NCI-2023-07361

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

This Phase 3 study aims to determine if adding HLX10, a new type of cancer-fighting medicine, to standard chemotherapy and radiation therapy benefits patients with early stage small cell lung cancer (SCLC). It's being conducted internationally and involves giving HLX10 or a placebo alongside chemotherapy and radiation therapy. The goal is to assess HLX10's effectiveness and safety in treating this type of lung cancer.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

small cell lung cancer (SCLC): A type of lung cancer with small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05353257

Clinical Trial Site: Einstein

To see all available clinical trials click here.